Company intelligence / Profile preview

Inotek Pharmaceuticals

Lexington, Massachusetts, United Statesinotekpharma.com ↗

Ownership: Private
Employees: ~11
Development stage: Other

Overview

Inotek's lead product trabodenoson failed in Phase 3 clinical trials for glaucoma in 2017, and a Phase 2 combination trial with latanoprost also failed to meet its primary endpoint, leading the company to seek strategic alternatives.

Therapeutic areas: OphthalmologyNeurology
Modalities: Small molecules
Industry: Biotech

Beyond the preview

Go deeper on Inotek Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inotek Pharmaceuticals.